Hepatology
Home Patients Clinicians Links

Currently Enrolling Clinical Trials for Liver Disease in the Northwest


Hemochromatosis

Studies of Phlebotomy Therapy in Hereditary Hemachromatosis: This study is for people who have hemochromatosis. This study looks at genetic response to phlebotomy, to evaluate the course of liver and rheumatologic disease and to look at safety and effectiveness of allogeneic transfusion. For information on these sites please call 1-800-411-1222.


Hepatitis B

Lamivudine for Chronic Hepatitis B: This study will investigate the safety and effectiveness of long-term therapy with Lamivudine. Patients with chronic hepatitis B will be treated with oral lamivudine at a dose of 100mg daily for up to 5 years. Patients who develop viral resistance will be offered higher doses of lamivudine (300mg daily). For information on these sites please call 1-800-411-1222.

Entecavir for Chronic Hepatitis B: This study will investigate the safety and effectiveness of an investigational drug called Entecavir. Patients with chronic hepatitis B either previously treated or untreated will be considered for entry. Participants will be randomized to either Entecavir 0.5 mg daily or Lamivudine 100mg daily for 1 year. This study is being done at the University of Washington. If interested please call the UW at (206) 221-4538.


Hepatitis C

Long Term Interferon Treatment for Chronic Hepatitis C: This study is for patients with chronic hepatitis C that have previously not responded to therapy and that have a liver fibrosis score of 3-6. Patients will receive Pegylated interferon plus ribavirin for a period of 6-12 months. For those that do not respond at 6 months, they will be re-randomized to either stop therapy or continue with Pegylated interferon alone for 31/2 years. Patients in this group will be brought in at years 2 and 4 for liver biopsy. For information on these sites please call 1-800-411-1222.

Long Term Therapy with Ribavirin for Chronic Hepatitis C: This study is for patients that have previously not responded to combination therapy or could not tolerate the side effects of combination therapy. Patients will receive ribavirin alone for a period of 6 months to 4 years depending on response. For information on these sites please call 1-800-411-1222.

Combination Drug Therapy for Patients with Hepatitis C: The purpose of this study is to determine whether the combination of interferon and ribavirin improve the liver disease of hepatitis C and whether improvements can me maintained by continuing ribavirin alone, long-term For information on these sites please call 1-800-411-1222.

Long Term Interferon for Previously Treated Non-Responders: This is called the HALT-C trial. The purpose of this trial is to determine if continuing interferon long term over several years will suppress the Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation. Patients will be treated with Pegylated Interferon plus Ribavirin for 6 months, those who respond will be treated for an addition 6 months, those who do not will be randomized to either receive Pegylated Interferon or discontinue treatment for 3.5 years. This study is being done at the following locations in the Northwest please call for more information:
University of California at Irvine (714) 456-7821
USC School of Medicine (323) 442-5550
University of Colorado (503) 315-4009

Pegylated Interferon and Weight based Ribavirin for Previously Untreated Adult Subjects: The purpose of this study is to look at the safety and effectiveness of using weight based ribavirin in combination with pegylated interferon. Patients will be treated with Pegylated Interferon 1.5 mcg/kg in combination with either 800mg of Ribavirin or weight based ribavirin 132 mg/kg for 48 weeks. This study is being done at multiple sites in Washington, Alaska, Utah, and Hawaii. Please call (206) 598-3236 for more information on participating sites.

Pegasys and Ribavirin for Chronic Hepatitis C: The purpose of this study is to look at the safety and effectiveness of Pegylated Interferon plus Ribavirin versus Pegylated Interferon alone in the treatment of adults with chronic hepatitis C. This study is being done at multiple sites within Washington. For more information on these sites please call 1-800-527-6243 X8001089.

Pegylated Interferon and Weight based Ribavirin for Previously Treated Non-Responders: The purpose of this study is to look at the safety and effectiveness of treating previously treated nonresponders with higher doses of Pegylated Interferon and Weight Based Ribavirin. Patients will be randomized to either receive 1.5 mcg/kg of Pegylated Interferon or 3.0mcg/kg of Pegylated interferon with weight based ribavirin for 48 weeks. This study is being done at multiple sites in Washington, Alaska, Utah, and Hawaii. Please call (206) 598-3236 for more information on participating sites.

Naturopathic Therapies: There are several research studies beginning, which involve the use of different naturopathic treatments for chronic hepatitis C. For more information please contact Bastyr Research Institute at (425) 602-3165.


HIV and Hepatitis C

A Comparison of Two Different Hepatitis C Treatments in Patients Infected with Both HIV and Hepatitis C: The purpose of the study is to look at the safety and effectiveness of Interferon plus Ribavirin versus Pegylated Interferon plus Ribavirin. The study will be looking at response of these patients to therapy as well as the effects of drug treatment on the levels of 2 anti-HIV drugs zidovudine and stavudine. This study is being done at multiple sites within California, Colorado and Hawaii. For information on these sites please call 1-800-411-1222.


Primary Biliary Cirrhosis

Evaluation of Patients with Liver Disease: The purpose of this study is to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study focuses on understanding diseases that affect the liver. For information on these sites please call 1-800-411-1222.


Primary Sclerosing Cholangitis

Evaluation of Patients with Liver Disease: The purpose of this study is to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study focuses on understanding diseases that affect the liver. For information on these sites please call 1-800-411-1222.


Top

©Copyright 2001   University of Washington. All rights reserved